Wantai Bio: The company's application for marketing authorization for nine-valent HPV vaccine was accepted

On August 26th, Wantai Bio announced in the evening that the application for marketing authorization of the nine-valent HPV vaccine jointly developed by Wantai Canghai, a wholly-owned subsidiary of the company, and Xiamen University has been accepted by the Drug Evaluation Center of the State Food and Drug Administration. According to the "Drug Registration Administration Measures", the State Food and Drug Administration will conduct a technical review of the safety, efficacy and quality controllability of the vaccine, and simultaneously carry out on-site verification of production and compliance inspection of pre-market drug production quality management norms. The nine-valent HPV vaccine needs to go through a long cycle from acceptance to approval for listing, and will not have a significant impact on the company's financial status and operating results in the short term.